Sightera Biosciences is a techbio company that uses artificial intelligence to discover and design new medicines, with a current focus on oncology and fibrosis. It generates proprietary datasets from patient-derived disease models to design novel small molecules informed by human disease biology.
Investment Rounds
Capital activity and funding progression
Frequently Asked Questions
Where is Sightera Biosciences located?
Sightera Biosciences is located in Antwerp, Belgium.
What industries does Sightera Biosciences operate in?
Sightera Biosciences operates in the following industries: Biotechnology Research, Artificial Intelligence, Drug Discovery.
How much total funding has Sightera Biosciences raised?
Sightera Biosciences has raised a total of $3,000,000.
Who are the investors in Sightera Biosciences?
The investors in Sightera Biosciences are: Entourage Ventures, Anacura, Qbic Fund.
What is the primary focus of Sightera Biosciences?
Sightera Biosciences is an AI-native drug discovery company that focuses on developing novel small molecules for oncology and regenerative medicine, particularly for solid tumors and fibrotic applications.
How does Sightera Biosciences differentiate its drug discovery process?
Unlike companies that rely on public or generic datasets, Sightera Biosciences trains its AI models using proprietary, clinically correlated data generated from patient-derived biological material, such as organoids and complex tumor microenvironment models.
Where is Sightera Biosciences headquartered and how was it formed?
Sightera Biosciences is based in Belgium and was formed as a spin-off from the University of Antwerp and the Antwerp University Hospital.
What business model does Sightera Biosciences follow?
Sightera Biosciences operates under a B2B model, functioning as an external innovation partner for mid- to large-sized pharmaceutical companies by offering flexible licensing models, from asset-based licensing to platform-based partnerships.
What is the SPAR technology used by Sightera Biosciences?
SPAR stands for Structure-Patient-Activity-Relationship. This unique technology integrates chemical structure analysis with patient-centered biological models to design therapies that reflect the desired therapeutic effect in targeted patient populations from the very start of the discovery process.